{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["He MM"],"funding":["American Cancer Society","Deutsche Forschungsgemeinschaft","National Natural Science Foundation of China","NCI NIH HHS","National Institutes of Health","Wellcome Trust","Natural Science Foundation of Jiangsu Province"],"pagination":["1867-1878"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8244830"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["148(8)"],"pubmed_abstract":["Evidence links the liver to development of colorectal cancer (CRC). However, it remains unknown how liver function may influence CRC risk in the general population. We conducted a prospective cohort study in the UK Biobank of 375 693 participants who provided blood samples in 2006 to 2010. Circulating levels of liver function markers (alanine transaminase [ALT], aspartate transaminase [AST], total bilirubin [TBIL], gamma glutamyltransferase [GGT], alkaline phosphatase [ALP], total protein [TP] and albumin [ALB]) were measured. Incident cancer cases were identified through linkage to the national cancer registry up to 2019. Repeated biomarker measurements were available from a subset of 11 320 participants who were re-assessed in 2012 to 2013. After a median follow-up of 10.0 years, we docu"],"journal":["International journal of cancer"],"pubmed_title":["Circulating liver function markers and colorectal cancer risk: A prospective cohort study in the UK Biobank."],"pmcid":["PMC8244830"],"funding_grant_id":["R00 CA215314","BK20190083","MRSG‐17‐220‐01‐NEC","81973127","DFG 426308975"],"pubmed_authors":["Lo CH","Polychronidis G","He MM","Wang F","Wang K","Knudsen MD","Wang L","Hang D","Fang Z","Song M","Zhong R","Xu RH","Smith SG"],"additional_accession":[]},"is_claimable":false,"name":"Circulating liver function markers and colorectal cancer risk: A prospective cohort study in the UK Biobank.","description":"Evidence links the liver to development of colorectal cancer (CRC). However, it remains unknown how liver function may influence CRC risk in the general population. We conducted a prospective cohort study in the UK Biobank of 375 693 participants who provided blood samples in 2006 to 2010. Circulating levels of liver function markers (alanine transaminase [ALT], aspartate transaminase [AST], total bilirubin [TBIL], gamma glutamyltransferase [GGT], alkaline phosphatase [ALP], total protein [TP] and albumin [ALB]) were measured. Incident cancer cases were identified through linkage to the national cancer registry up to 2019. Repeated biomarker measurements were available from a subset of 11 320 participants who were re-assessed in 2012 to 2013. After a median follow-up of 10.0 years, we docu","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2025-04-22T21:54:01.274Z","creation":"2025-04-06T03:53:21.605Z"},"accession":"S-EPMC8244830","cross_references":{"pubmed":["33091956"],"doi":["10.1002/ijc.33351"]}}